Patents Assigned to Japanese Red Cross Society
-
Patent number: 9079961Abstract: An object of the present invention is to provide a probe, primer, primer set and antibody for determining neonatal alloimmune thrombocytopenic purpura or the risk of developing it. According to the present invention, there is provided a probe, primer, primer set and antibody for use in the detection of the thymine residue at position 1297 in the GPIIIa.Type: GrantFiled: May 26, 2008Date of Patent: July 14, 2015Assignees: JAPANESE RED CROSS SOCIETY, WAKUNAGA PHARMACEUTICAL CO., LTD.Inventors: Atsuko Taniue, Hiroyuki Ishii, Shinji Maekawajiri, Nozomi Nagata, Takanori Oka
-
Patent number: 8367391Abstract: A pretreatment method of a specimen used for detecting or determining abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE), wherein (1) a specimen which had been treated with proteinase K is heated in the presence of sodium dodecyl sulfate (SDS) to dissolve proteins and inactivate infectious activity in the specimen at the same time; (2) the specimen processed in the above (1) is cooled under a neutral condition to make abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE) aggregated; (3) the aggregate formed in the above (2) is separated from a solution; and (4) the separated PrPres aggregate is detected by the ultrasensitive chemiluminescence method.Type: GrantFiled: August 22, 2008Date of Patent: February 5, 2013Assignee: Japanese Red Cross SocietyInventor: Kazuo Tsukui
-
Patent number: 8008028Abstract: A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody.Type: GrantFiled: March 13, 2007Date of Patent: August 30, 2011Assignees: Japanese Red Cross Society, Wakunaga Pharmaceutical Co., Ltd.Inventors: Kazuta Yasui, Fumiya Hirayama, Rika Furuta, Nobuki Matsuyama, Yoshitaka Kojima, Toru Miyazaki, Hisami Ikeda, Yoshihisa Watanabe
-
Publication number: 20110195407Abstract: A substance associated with cryptogenic hepatitis is found and information, particularly genetic information, on the substance is provided. Also, a method for detecting the substance and a material which can be used in the method are provided. A nucleic acid is extracted from each of 500 blood samples which have alanine aminotransferase (ALT) abnormality and are negative for a hepatitis virus marker, and the amplification of the nucleic acid is carried out by using helicase family-reactive helicase primers which have been produced uniquely. As a result, a novel nucleotide sequence (SEQ ID NO:1) can be obtained, and it is found that the nucleotide sequence occurs at high frequency in cryptogenic hepatitis.Type: ApplicationFiled: August 3, 2009Publication date: August 11, 2011Applicant: Japanese Red Cross SocietyInventors: Kouei Satoh, Akiko Takakura
-
Publication number: 20110053791Abstract: A pretreatment method of a specimen used for detecting or determining abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE), wherein (1) a specimen which had been treated with proteinase K is heated in the presence of sodium dodecyl sulfate (SDS) to dissolve proteins and inactivate infectious activity in the specimen at the same time; (2) the specimen processed in the above (1) is cooled under a neutral condition to make abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE) aggregated; (3) the aggregate formed in the above (2) is separated from a solution; and (4) the separated PrPres aggregate is detected by the ultrasensitive chemiluminescence method.Type: ApplicationFiled: August 22, 2008Publication date: March 3, 2011Applicant: Japanese Red Cross SocietyInventor: Kazuo Tsukui
-
Publication number: 20080281247Abstract: An autonomic nervous activity monitor capable of predicting occurrence of abnormal reaction depending on autonomic nervous activity and used for medical practice and the like is provided. A blood component collecting apparatus 100 carries out frequency analysis to a pattern of heartbeat which is acquired by an ECG 300 from a donor, and calculates a high frequency component value [msec2] defined as an indicator for parasympathetic activity and a ratio value of a low frequency component to the high frequency component defined as an indicator for sympathetic activity to detect a change in these values on a time-series base. When a judgment circuit 204 predicts that abnormal reaction may occur to a donor after blood collection operation is started, a controller 200 controls a pump 9 to decrease a blood drawing or blood returning speed, or, to stop blood drawing or blood returning operation.Type: ApplicationFiled: July 11, 2008Publication date: November 13, 2008Applicants: Japanese Red Cross Society, TERUMO KABUSHIKI KAISHAInventors: Kenji Tadokoro, Fumiko Saitou, Yoshiki Takagi
-
Patent number: 7413548Abstract: An autonomic nervous activity monitor capable of predicting occurrence of abnormal reaction depending on autonomic nervous activity and used for medical practice and the like is provided. A blood component collecting apparatus 100 carries out frequency analysis to a pattern of heartbeat which is acquired by an ECG 300 from a donor, and calculates a high frequency component value [msec2] defined as an indicator for parasympathetic activity and a ratio value of a low frequency component to the high frequency component defined as an indicator for sympathetic activity to detect a change in these values on a time-series base. When a judgment circuit 204 predicts that abnormal reaction may occur to a donor after blood collection operation is started, a controller 200 controls a pump 9 to decrease a blood drawing or blood returning speed, or, to stop blood drawing or blood returning operation.Type: GrantFiled: March 18, 2005Date of Patent: August 19, 2008Assignees: Japanese Red Cross Society, Terumo Kabushiki KaishaInventors: Kenji Tadokoro, Fumiko Saitou, Yoshiki Takagi
-
Publication number: 20050209522Abstract: An autonomic nervous activity monitor capable of predicting occurrence of abnormal reaction depending on autonomic nervous activity and used for medical practice and the like is provided. A blood component collecting apparatus 100 carries out frequency analysis to a pattern of heartbeat which is acquired by an ECG 300 from a donor, and calculates a high frequency component value [msec2] defined as an indicator for parasympathetic activity and a ratio value of a low frequency component to the high frequency component defined as an indicator for sympathetic activity to detect a change in these values on a time-series base. When a judgment circuit 204 predicts that abnormal reaction may occur to a donor after blood collection operation is started, a controller 200 controls a pump 9 to decrease a blood drawing or blood returning speed, or, to stop blood drawing or blood returning operation.Type: ApplicationFiled: March 18, 2005Publication date: September 22, 2005Applicants: Japanese Red Cross Society, TERUMO KABUSHIKI KAISHAInventors: Kenji Tadokoro, Fumiko Saitou, Yoshiki Takagi
-
Patent number: 6413716Abstract: A method for detection of human parvovirus B19, comprising the steps of: (1) bringing a sample into contact with fixed P-antigen positive red cells in a medium at pH 5.6±0.6; and (2) determining whether or not hemagglutination occurs; and a reagent for detecting human parvovirus B19, wherein the reagent comprises fixed P-antigen positive red cells.Type: GrantFiled: June 18, 1996Date of Patent: July 2, 2002Assignee: The Japanese Red Cross SocietyInventors: Fumihiro Takakura, Hiroyuki Sato, Yoshiaki Maeda
-
Patent number: 5219999Abstract: Crude immunoglobulin G isolated from human blood plasma is treated according to a conventional technique (such as the tricalcium phosphate adsorption method) to remove aggregates therefrom to such an extent that they are not detectable by gel filtration analysis. In order to produce an aqueous solution of immunoglobulin G having a reduced anticomplementary activity, the resulting solution is then filtered through a porous polyolefin membrane having a pore size larger than the molecular size of immunoglobulin G, in the presence of a stabilizer having surface activity. The aqueous solution of immunoglobulin G so produced is suitable for use in intravenous injection because its anticomplementary activity is low.Type: GrantFiled: March 15, 1991Date of Patent: June 15, 1993Assignees: Mitsubishi Rayon Co., Ltd., The Japanese Red Cross SocietyInventors: Tohru Suzuki, Hiroyuki Ikeda, Kazuyo Ikeda, Tsugikazu Tomono, Sadayoshi Sekiguchi, Takeji Ohtani, Seigi Suzuki
-
Patent number: 4880786Abstract: There is disclosed an additive solution for blood preservation and activation, which comprises a phosphoenolpyruvic acid represented by the following formula (I): ##STR1## wherein R.sub.1 represents a hydrogen atom or an alkyl group having 1 to 12 carbon atoms, R.sub.2 and R.sub.3 represent a hydrogen atom, an alkali metal or an alkyl group having 1 to 12 carbon atoms, respectively,an L-ascorbic acid-phosphate or its pharmaceutically acceptable salt, a saccharide, adenine and a pharmaceutically acceptable organic buffer.Type: GrantFiled: January 11, 1988Date of Patent: November 14, 1989Assignees: Ube Industries, Ltd., Showa Denko K.K., The Japanese Red Cross SocietyInventors: Shigeru Sasakawa, Masayuki Shiba
-
Patent number: 4769318Abstract: There is disclosed an additive solution for blood preservation and activation, which comprises a phosphoenolpyruvic acid represented by the following formula (I): ##STR1## wherein R.sub.1 represents a hydrogen atom or an alkyl group having 1 to 12 carbon atoms, R.sub.2 and R.sub.3 represent a hydrogen atom, an alkali metal or an alkyl group having 1 to 12 carbon atoms respectively, a saccharide, adenine and an organic acid and/or a pharmaceutically acceptable alkali metal salt of the organic acid.Type: GrantFiled: April 15, 1987Date of Patent: September 6, 1988Assignees: Ube Industries, Ltd., The Japanese Red Cross SocietyInventors: Naotaka Hamasaki, Shigeru Sasakawa, Masayuki Shiba